Back to Back Issues Page
Dry AMD Study to Reduce Geographic Atrophy Progression
January 04, 2017
Hello

Dry AMD Study to Reduce Geographic Atrophy Progression

"The phase 2 proof-of-concept MAHALO study showed a 20% reduction in the area of geographic atrophy with monthly treatment, rising to 44% in a biomarker-defined subset," reports Ocular Surgery News Europe Edition, February 2016.

These positive results are hoping to be duplicated in a Phase III clinical trial called SPECTRI. This dry macular degeneration clinical trial will treat participants with 10 mg of lampalizumab in the form of eye injections every 4 or 6 weeks while another group will receive sham or placebo injections.

“If the results of MAHALO can be replicated in a larger group of patients, Roche will start the procedure to register this drug for the treatment of geographic atrophy,” states Jordi Monés, MD, PHD and one of the investigators of another clinical trial using lampalizumab.

Find out more about this study and how it can impact the progression of dry AMD.

SPECTRI and Other Dry Macular Degeneration Research Studies

Leslie Degner, RN, BSN

Better Health for Better Vision

www.WebRN-MacularDegeneration.com

Back to Back Issues Page